![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Phase 2b Study of MK-7009 (vaniprevir) in Patients with Genotype 1 HCV Infection Who HaveFailed Previous Pegylated Interferon and Ribavirin Treatment
|
|
|
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
Eric Lawitz1, Maribel Rodriguez-Torres2, Albrecht Stoehr3, Edward J. Gane4, Lawrence Serfaty5, Sanhita Bhanja6, Richard J. Barnard6, Di An6, Jacqueline Gress6, Peggy Hwang6, Niloufar Mobashery6
1Alamo Medical Research, San Antonio, TX, United States; 2Fundacion de Investigacion, San Juan, Puerto Rico; 3IFI - Institut fur Interdisziplinäre Medizin, Hamburg, Germany; 4Auckland Clinical Studies Ltd, Auckland, New Zealand;5Service d'Hepatologie, Hopital Saint-Antoine, Universite Pierre et Marie Curie, Paris, France; 6Merck and Company, North Wales, PA, United States
![AASLD1.gif](../images/111411/111411-11/AASLD1.gif)
![AASLD2.gif](../images/111411/111411-11/AASLD2.gif)
![AASLD3.gif](../images/111411/111411-11/AASLD3.gif)
![AASLD4.gif](../images/111411/111411-11/AASLD4.gif)
![AASLD5.gif](../images/111411/111411-11/AASLD5.gif)
![AASLD6.gif](../images/111411/111411-11/AASLD6.gif)
![AASLD7.gif](../images/111411/111411-11/AASLD7.gif)
![AASLD8.gif](../images/111411/111411-11/AASLD8.gif)
![AASLD9.gif](../images/111411/111411-11/AASLD9.gif)
![AASLD10.gif](../images/111411/111411-11/AASLD10.gif)
![AASLD11.gif](../images/111411/111411-11/AASLD11.gif)
![AASLD12.gif](../images/111411/111411-11/AASLD12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|